Advertisement

Korean Stem Cell Med for Sale

South Korea approves the first stem-cell medication for clinical use.

By | July 8, 2011

LEONARDINI / STOCK.XCHNG

After six years of clinical trials, the South Korean Food and Drug Administration approved a stem-cell-based treatment for commercial sale last week—making South Korea the first country where a stem cell medication has been green-lighted for clinical use. Developed by FCB-Pharmicell, a Korean biotech that specializes in stem cell drugs, Hearticellgram-AMI consists of an injection of somatic stem cells cultured from the bone marrow into the coronary arteries of patients who have suffered from acute myocardial infarction. According to the company, just one injection is enough to promote a 6 percent improvement in heart function after 6 months. However, there has been concern over a lack of independent validation of the treatment, Reuters reports, as FCB-Pharmicell’s new product is yet to be vetted by a peer review publication.

Advertisement

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Advertisement
Life Technologies